Home › NDC Lookup › RxCUI directory › RxCUI 1729308

Aprepitant 125 MG Powder for Oral Suspension — RxCUI 1729308

Name: Aprepitant 125 MG Powder for Oral Suspension (RxCUI 1729308)
Creator: Brian Staiger, PharmD

RxNorm drug concept · Semantic clinical drug

RxCUI 1729308 Semantic clinical drug · SCD ● Current RxNorm concept 5 FDA products 5 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by Dr. Brian Staiger, PharmD

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1729308

Official nameAprepitant 125 MG Powder for Oral Suspension

Concept typeSemantic clinical drug (SCD)

RxNorm statusCurrent RxNorm concept

FDA products mapped5

Package NDCs mapped5

Reported Medicaid activity (SDUD)482 prescriptions · 9 state & territory Medicaid programs · latest period Q4 2025

RxNorm release07/06/2026

Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Aprepitant: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist

Aprepitant is designed to prevent nausea and vomiting before they start — not to treat them once they've kicked in. It's given as part of a combination of anti-nausea medicines, us...
What exactly is this medicine supposed to do for me?
Not without a backup plan. Aprepitant can reduce how well hormonal birth control works — that includes the pill, the patch, implants, and some IUDs. This effect can last for a full...
Can I take my birth control as usual while I'm on this?

📖 Read our full Aprepitant guide →

🕸️ Concept Web — How Aprepitant 125 MG Powder for Oral Suspension Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.

This page's concept Aprepitant 125 MG Powder for Oral Suspension RxCUI 1729308 Semantic clinical drug · SCD

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

Ingredients 1

The active substance itself — no strength, form, or brand attached yet.
- Aprepitant 358255 IN
Brand names 1

The same medicine's trade names. A brand name alone says nothing about strength or form.
- Emend 357280 BN
Dose forms 9

The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
- Aprepitant Powder for Oral Suspension 1729307 SCDF
- Aprepitant Oral Powder Product 1729306 SCDG
- Aprepitant Oral Product 1157722 SCDG
- Aprepitant Powder for Oral Suspension [Emend] 1729309 SBDF
- Emend Oral Powder Product 1729310 SBDG
- Emend Oral Product 1175305 SBDG
- Powder for Oral Suspension 1540456 DF
- Oral Powder Product 1294711 DFG
- +1 more in this family
Clinical & branded drugs 3

Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
- Aprepitant 125 MG 405797 SCDC
- Aprepitant 125 MG Powder for Oral Suspension [Emend] 1729311 SBD
- Aprepitant 125 MG [Emend] 576420 SBDC

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.

These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

Aprepitant 125 MG SCDC · 405797
Aprepitant Powder for Oral Suspension SCDF · 1729307
Aprepitant Oral Powder Product SCDG · 1729306
Aprepitant Oral Product SCDG · 1157722

Brand-Name Concepts

Aprepitant 125 MG Powder for Oral Suspension [Emend] SBD · 1729311
Aprepitant 125 MG [Emend] SBDC · 576420
Aprepitant Powder for Oral Suspension [Emend] SBDF · 1729309
Emend Oral Powder Product SBDG · 1729310
Emend Oral Product SBDG · 1175305
Emend BN · 357280

📦 FDA Products & Package NDCs

5 products · 5 package NDCs

5 package NDCs map to RxCUI 1729308 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.

Package NDC	Package	Brand / generic name	Labeler	Marketing start
00006-0461-02	2 CAPSULE in 1 DOSE PACK (0006-0461-02)	EMEND	Merck Sharp & Dohme LLC	2003-03-26
00006-0461-12	2 CAPSULE in 1 DOSE PACK (0006-0461-12)	EMEND	Merck Sharp & Dohme LLC	2003-03-26
00006-3066-03	1 POUCH in 1 CARTON (0006-3066-03) / 1 POWDER, FOR SUSPENSI...	EMEND	Merck Sharp & Dohme LLC	2015-12-17
00006-3862-03	1 KIT in 1 DOSE PACK (0006-3862-03) * 1 CAPSULE in 1 CAPSU...	EMEND	Merck Sharp & Dohme LLC	2003-03-26
00006-3862-13	1 KIT in 1 DOSE PACK (0006-3862-13) * 1 CAPSULE in 1 CAPSU...	EMEND	Merck Sharp & Dohme LLC	2003-03-26

Observed labelers: Merck Sharp & Dohme LLC (5) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🧾 Billing Codes (HCPCS)

Medical billing codes (HCPCS "J-codes") that connect to this concept's packages — used mostly when a clinic or hospital bills for a drug it administers. Each code links to its full billing page.

Code	Descriptor	Mapped packages	Sources
J8501	Oral aprepitant	3	CMS

⚠ A crosswalk is not coverage: an NDC↔HCPCS mapping does not guarantee any payer covers or pays the code. Always verify the current payer policy before billing.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7

openFDA export observedJul 14, 2026

RxNorm release07/06/2026

Methodology2026-07-full-catalog-v1

A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.

This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.